Biocon Pharma Limited, a subsidiary of Biocon Limited, received approval of its ANDA for Mycophenolic Acid from the US FDA. This product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available in 180mg and 360mg strengths. This approval further adds to Biocon's portfolio of vertically integrated complex drug products.
Shares of Biocon Limited was last trading in BSE at Rs. 367.25 as compared to the previous close of Rs. 371.25. The total number of shares traded during the day was 254078 in over 5694 trades.
The stock hit an intraday high of Rs. 378.40 and intraday low of 363.00. The net turnover during the day was Rs. 94111269.00.